GW Pharmaceuticals reports the results of phase 3 study of Epidiolex for treatment of Dravet syndrome, a rare and severe form of epilepsy. This post from Clinical Leader gives the study overview and discusses the phase 3 trial results. GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, ... Continue Reading